

WUENIC Talking Points: Türkiye

Revision Year: 2025

Contents

Overview	2
DTP1: Reaching zero-dose children	3
DTP3: A marker of routine immunization service delivery to children	4
MCV: Canary in the coal mine	5
HPV	6
Regional Comparison	7
Additional Vaccines	8
Appendix	9


Türkiye in the 'Asia' region



Overview


- A total of 12 childhood vaccines are tracked for Türkiye; of these, 12 reached the 90% coverage target or higher in 2025.
- Coverage of the first dose of diphtheria-tetanus-pertussis-containing vaccine (DTP1) declined from 96% in 2024 to 94% in 2025, coverage of the third dose of DTP-containing vaccine (DTP3) declined from 96% in 2024 to 94% in 2025, and coverage of the first dose of the measles-containing vaccine (MCV1) declined from 94% in 2024 to 92% in 2025.
- In 2025, the number of zero-dose children for DTP in Türkiye (63,000) was approximately 575% higher than the annual number proposed to achieve the IA2030 target of halving zero-dose children for DTP by 2030 (9,000), based on a linear trajectory of decline.

Vaccine coverage (%), Türkiye, 2000–2025



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.


Estimated number of zero-dose children, 2000–2025 and target by 2030, Türkiye



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.
 Note: The Immunization Agenda 2030 (IA2030) calls on all countries to reduce the number of zero-dose children in 2019 in half by 2030.
 Dark blue bars are the estimated number of zero-dose children in 2000–2025,
 light blue bar is the target number of zero-dose children by 2030.
 The line and points show the yearly progress and trajectory to meet the target by 2030, based on a linear decline.

DTP1: Reaching zero-dose children


- Coverage of DTP1 stood at 94% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (96%).
- The percentage of zero-dose children was 575 percentage points higher than the IA2030 target in 2025. There were approximately 63,000 zero-dose children in 2025, more than the 13,000 in 2019 and more than the 42,000 in 2024.
- Coverage of DTP1 in Türkiye (94%) was higher than the Eastern Europe and Central Asia regional average of 90% in 2025.
- DTP1-to-DTP3 dropout in 2025 was 0%, the same as in 2019. Low DTP dropout rates imply good ability to provide a complete vaccine series early in life.



Dotted line shows the IA2030 target of 90% coverage
Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

DTP3: A marker of routine immunization service delivery to children


- Coverage of DTP3 stood at 94% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (96%).
- The number of children vaccinated with DTP3 decreased from 1.3 million in 2019 to 983,000 in 2025.
- In 2025, there were 63,000 children un- or under-vaccinated in Türkiye.
- In 2025, 0% of children who received DTP1 did not receive DTP3. This 0% dropout rate was the same as in 2019 (0%) and the same as the 2024 dropout rate (0%).
- Coverage of DTP3 in Türkiye (94%) was higher than the Eastern Europe and Central Asia regional average of 87% in 2025.



Dotted line shows the IA2030 target of 90% coverage
Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

MCV: Canary in the coal mine

- Coverage of MCV1 stood at 92% in 2025. This is lower than in 2019 (97%) and lower than in 2024 (94%).
- Coverage of the second dose of the measles-containing vaccine (MCV2) increased from 88% in 2019 to 91% in 2025. This leaves 84,000 children without any protection against measles and another 19,000 with only partial protection.
- In 2025, 2% of children who received DTP1 did not receive MCV1. This 2% dropout rate was the same as in 2019 (2%) and the same as the 2024 dropout rate (2%).
- Türkiye has achieved MCV1 coverage above 80% over all of the last 3 years.
- Coverage of MCV1 in Türkiye (92%) was higher than the Eastern Europe and Central Asia regional average of 88% in 2025.



Dotted line shows the IA2030 target of 90% coverage
Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

HPV


- Turkiye had not introduced human pappilomavirus vaccination (HPV) as of 2025.

Regional Comparison

The chart below shows how Türkiye compares to other countries in the Eastern Europe and Central Asia region on DTP1, DTP3, MCV1 coverage in 2025. The dashed line represents the regional average for each vaccine.

Coverage comparison: Türkiye vs. ECAR peers, 2025

Dashed line = regional average



● Türkiye ● Peers

Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

Additional Vaccines

- Coverage of BCG stood at 93% in 2025. This is lower than in 2019 (96%) and lower than in 2024 (95%).
- Coverage of HepB3 stood at 93% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (95%).
- Coverage of Hib3 stood at 94% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (96%).
- Coverage of IPV1 stood at 94% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (96%).
- Coverage of PCVC stood at 92% in 2025. This is lower than in 2019 (97%) and lower than in 2024 (94%).

Additional vaccine coverage (%), Türkiye, 2000–2025

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
BCG	96	95	89	88	85	88	88	94	96	96	97	96	96	96	95	96	96	93	96	96	96	95	98	96	95	93
HepB3	71	77	72	68	77	85	82	96	92	94	96	96	97	97	96	97	98	96	98	99	98	96	99	99	95	93
Hib3								76	96	96	97	97	97	98	96	97	98	96	98	99	98	95	99	99	96	94
IPV1																98	99	98	99	99	98	95	99	99	96	94
PCVC									97	93	96	97	97	96	97	98	96	97	97	95	96	95	95	94	92	



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

Appendix

WHO/UNICEF Estimates of National Immunization Coverage (WUENIC)

Each year, WHO and UNICEF review national immunization data from Member States, including administrative and official coverage, survey estimates and contextual information, and use rules-based data triangulation approach to assess coverage. Estimates are produced independently, without borrowing data from other countries, and are not based on ad hoc adjustments. In some cases, they rely on a single source, typically nationally reported coverage. When data for a specific country-vaccine-year are unavailable, values from adjacent years are interpolated or extrapolated, and conflicting sources are assessed to determine the most reliable estimate, considering potential biases and expert opinion.

Methods:

- [Burton et al. 2009. WHO and UNICEF estimates of national infant immunization coverage: methods and processes](#)
- [Burton et al. 2012. A formal representation of the WHO and UNICEF estimates of national immunization coverage: a computational logic approach](#)
- [Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around the WHO and UNICEF estimates of national immunization coverage](#)

These talking points present the latest WUENIC estimates (published 15 July 2026).

Definitions of immunization terms:

- Bacillus Calmette-Guerin (BCG): vaccine against tuberculosis
- Hepatitis B birth dose, given within 24 hours after birth (HepBB)
- Diphtheria, tetanus, and pertussis vaccine, first dose (DTP1) and third dose (DTP3)
- Hepatitis B vaccine, third dose (HepB3)
- Haemophilus influenzae type B vaccine, third dose (Hib3)
- Inactivated polio vaccine, first dose (IPV1) and last dose (IPVC)
- Measles containing vaccine, first dose (MCV1) and second dose (MCV2)
- Rotavirus vaccine, last dose (RotaC)
- Pneumococcal vaccine, last dose (PCV)
- Yellow Fever vaccine (YFV)
- Meningococcal A vaccine (MengA)
- Human Papillomavirus vaccine, first dose (HPV1) and last dose (HPVc)

Additional resources: <https://data.unicef.org/resources/immunization/>